id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0805-0002,FDA,FDA-2011-N-0805,Dermatologic and Ophthalmic Drugs Advisory Committee; Amendment,Notice,General Notice,2012-02-14T05:00:00Z,2012,2,2012-02-14T05:00:00Z,,2012-03-24T19:28:27Z,2012-03343,0,0,0900006480fb557c